{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:53:32Z","timestamp":1772121212542,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.maturitas.2010.07.002","type":"journal-article","created":{"date-parts":[[2010,8,5]],"date-time":"2010-08-05T04:47:40Z","timestamp":1280983660000},"page":"227-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17\u03b2-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: Results from a double-blind, controlled study"],"prefix":"10.1016","volume":"67","author":[{"given":"John C.","family":"Stevenson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Durand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke","family":"Kahler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Perty\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2010.07.002_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1477-7525-3-47","article-title":"Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review","volume":"3","author":"Utian","year":"2005","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.maturitas.2010.07.002_bib2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00042192-200205000-00003","article-title":"A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century","volume":"9","author":"R\u00f6dstr\u00f6m","year":"2002","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2010.07.002_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/01.GME.0000108177.85442.71","article-title":"Treatment of menopause-associated vasomotor symptoms: position statement of the North American Menopause Society","volume":"11","author":"North American Menopause Society","year":"2004","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2010.07.002_bib4","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/GRF.0b013e31818093f6","article-title":"Symptoms of menopause: hot flushes","volume":"51","author":"Santoro","year":"2008","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2010.07.002_bib5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/gme.0b013e3181d0f6b9","article-title":"Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society","volume":"17","author":"North American Menopause Society","year":"2010","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2010.07.002_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13697130701361657","article-title":"IMS updated recommendations on postmenopausal hormone therapy","volume":"10","author":"Board of the International Menopause Society","year":"2007","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2010.07.002_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4158\/EP.12.3.315","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause","volume":"12","author":"AACE Menopause Guidelines Revision Task Force","year":"2006","journal-title":"Endocr Pract"},{"key":"10.1016\/j.maturitas.2010.07.002_bib8","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa030808","article-title":"Estrogen plus progestin and the risk of coronary heart disease","volume":"349","author":"Manson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2010.07.002_bib9","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1001\/jama.295.17.2057","article-title":"Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis","volume":"295","author":"Nelson","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2010.07.002_bib10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00404-007-0390-9","article-title":"Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidence-based review","volume":"276","author":"Cheema","year":"2007","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.maturitas.2010.07.002_bib11","first-page":"21","article-title":"Estrace\u00ae vs Premarin\u00ae for treatment of menopausal symptoms: dosage comparison study","volume":"9","author":"Archer","year":"1992","journal-title":"Adv Ther"},{"key":"10.1016\/j.maturitas.2010.07.002_bib12","first-page":"726","article-title":"Initial 17beta-estradiol dose for treating vasomotor symptoms","volume":"95","author":"Notelovitz","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2010.07.002_bib13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00042192-200007050-00005","article-title":"Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta-estradiol","volume":"7","author":"Notelovitz","year":"2000","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2010.07.002_bib14","unstructured":"http:\/\/www.fda.gov\/cder\/foi\/label\/2003\/21396_prempro_lbl.pdf."},{"key":"10.1016\/j.maturitas.2010.07.002_bib15","first-page":"16","article-title":"Evaluation of climacteric symptoms (Menopause Rating Scale)","volume":"116","author":"Hauser","year":"1994","journal-title":"Zentralbl Gynakol"},{"key":"10.1016\/j.maturitas.2010.07.002_bib16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1477-7525-1-28","article-title":"International versions of the Menopause Rating Scale (MRS)","volume":"1","author":"Heinemann","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.maturitas.2010.07.002_bib17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1055\/s-2005-869479","article-title":"Pathophysiology and treatment of menopausal hot flashes","volume":"23","author":"Freedman","year":"2005","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.maturitas.2010.07.002_bib18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0015-0282(01)03009-6","article-title":"Estrogen raises the sweating threshold in postmenopausal women with hot flashes","volume":"77","author":"Freedman","year":"2002","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2010.07.002_bib19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(03)14596-5","article-title":"Breast cancer and hormone-replacement therapy in the Million Women Study","volume":"362","author":"Beral","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2010.07.002_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.maturitas.2007.02.025","article-title":"Rationale for the use of lower estrogen doses for postmenopausal hormone therapy","volume":"57","author":"Ettinger","year":"2007","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2010.07.002_bib21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s12325-008-0070-6","article-title":"Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5mg\/NETA 0.1mg","volume":"25","author":"Johansen","year":"2008","journal-title":"Adv Ther"},{"key":"10.1016\/j.maturitas.2010.07.002_bib22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/13697130701298107","article-title":"Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief","volume":"10","author":"Panay","year":"2007","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2010.07.002_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.maturitas.2006.08.004","article-title":"Benefits and risks of long-term low-dose oral continuous combined hormone therapy","volume":"56","author":"van de Weijer","year":"2007","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2010.07.002_bib24","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.maturitas.2005.05.015","article-title":"Continuous combined hormone replacement therapy with 1mg 17\u03b2-oestradiol and 5mg dydrogesterone (Femoston-conti): endometrial safety and bleeding profile","volume":"53","author":"Quereux","year":"2006","journal-title":"Maturitas"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512210002781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512210002781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:49:53Z","timestamp":1759913393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512210002781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0378512210002781"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2010.07.002","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.4895957.4826055","asserted-by":"object"}]},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral ultra-low dose continuous combined hormone replacement therapy with 0.5mg 17\u03b2-oestradiol and 2.5mg dydrogesterone for the treatment of vasomotor symptoms: Results from a double-blind, controlled study","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2010.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}